Altre lingue LigaChem Biosciences Inc.

Azioni

A141080

KR7141080002

Biotecnologia

Prezzo di chiusura Korea S.E. Altri mercati azionari 16/01/2026			Variaz. 5gg	Var. 1 gen.
166.800,00 ^KRW	+2,33%		-9,54%	-3,97%

14/11	LigaChem Biosciences Inc.: Risultati Finanziari del Terzo Trimestre e dei Primi Nove Mesi al 30 Settembre 2025	CI
01/10/25	Ligachem Biosciences cede azioni proprie per un valore di 5 miliardi di won	RE

Altre lingue

14/11	LigaChem Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
01/10/25	Ligachem Biosciences to divest 5 billion won worth of own shares
14/08/25	LigaChem Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
27/06/25	Tranche Update on LigaChem Biosciences Inc.'s Equity Buyback Plan announced on March 25, 2025.
29/05/25	NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
15/05/25	LigaChem Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
08/04/25	Ligachem Biosciences To Divest 17 Billion Won Worth Of Own Shares
08/04/25	Tranche Update on LigaChem Biosciences Inc.'s Equity Buyback Plan announced on October 14, 2024.
08/04/25	Tranche Update on LigaChem Biosciences Inc.'s Equity Buyback Plan announced on October 14, 2024.
08/04/25	LegoChem Biosciences, Inc.'s Equity Buyback announced on October 14, 2024, has expired with of 188,321 shares, representing 0.52% for KRW 19,956.38 million.
25/03/25	LigaChem Biosciences Inc. announces an Equity Buyback for KRW 7,000 million worth of its shares.
25/03/25	LigaChem Biosciences Inc. authorizes a Buyback Plan.
21/03/25	LigaChem Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
25/02/25	Wuxi Xdc Cayman Inc. and Ligachem Biosciences Strengthen Partnership with Expanded Mou to Accelerate Adc Development
20/01/25	Tranche Update on LigaChem Biosciences Inc.'s Equity Buyback Plan announced on October 14, 2024.
17/01/25	Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility
10/01/25	Samsung Biologics Expands ADC Collaboration with LigaChem Biosciences
09/01/25	Samsung Biologics Extends Collaboration with Ligachem Biosciences for Adc Development
14/11/24	LigaChem Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
23/10/24	LigaChem Biosciences Inc. Appoints Rodrigo Ruiz Soto as Chief Medical Officer
14/10/24	LigaChem Biosciences Inc. announces an Equity Buyback for KRW 20,000 million worth of its shares.
14/10/24	LigaChem Biosciences Inc. authorizes a Buyback Plan.
11/10/24	LigaChem Biosciences Signs $700 Million License Deal for Anti-Cancer Drug
14/08/24	LigaChem Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
16/05/24	LigaChem Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Articoli MarketScreener Analisi MarketScreener Idee di trading

Altre lingue LigaChem Biosciences Inc.

Azioni

A141080

KR7141080002

Biotecnologia

Altre lingue

Filtri